These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM; Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874 [TBL] [Abstract][Full Text] [Related]
4. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy]. Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297 [TBL] [Abstract][Full Text] [Related]
5. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy. Clumeck N Antivir Ther; 1998; 3 Suppl 4():39-43. PubMed ID: 10723508 [TBL] [Abstract][Full Text] [Related]
6. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849 [TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature. Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944 [TBL] [Abstract][Full Text] [Related]
8. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827 [TBL] [Abstract][Full Text] [Related]
10. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457 [TBL] [Abstract][Full Text] [Related]
11. Initiation of antiretroviral therapy: implications of recent findings. Saag MS Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939 [TBL] [Abstract][Full Text] [Related]
12. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine. Prescrire Int; 2005 Apr; 14(76):54-6. PubMed ID: 15875341 [TBL] [Abstract][Full Text] [Related]
14. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821 [TBL] [Abstract][Full Text] [Related]
15. Anti-HIV drugs. De Clercq E Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060 [TBL] [Abstract][Full Text] [Related]
16. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine. Fisher M AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718 [TBL] [Abstract][Full Text] [Related]
17. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. Pinheiro Edos S; Antunes OA; Fortunak JM Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246 [TBL] [Abstract][Full Text] [Related]
18. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030 [TBL] [Abstract][Full Text] [Related]